Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07609251 SCTB41 Locally Advanced Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07609251 clinical trial report covering SCTB41, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07610278 Inclisiran sodium Heterozygous familial hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07610278 clinical trial report covering Inclisiran sodium, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07608978 Zanubrutinib Diffuse Large B-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07608978 clinical trial report covering Zanubrutinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07609121 Tislelizumab Non-small cell lung cancer stage III Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07609121 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07608796 Baricitinib Depressive Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07608796 clinical trial report covering Baricitinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07608770 Resveratrol/Curcumin Subcutaneous fat disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07608770 clinical trial report covering Resveratrol/Curcumin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07608354 Eplontersen Transthyretin Amyloid Cardiomyopathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07608354 clinical trial report covering Eplontersen, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07609667 Tislelizumab Metastatic Gastroesophageal Junction Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07609667 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07609472 FG-001 High grade glioma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07609472 clinical trial report covering FG-001, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07608718 Zanzalintinib Metastatic castration-resistant prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07608718 clinical trial report covering Zanzalintinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07609823 Lacutoclax Recurrent Chronic Lymphoid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07609823 clinical trial report covering Lacutoclax, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07608757 Resveratrol/Curcumin Subcutaneous fat disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07608757 clinical trial report covering Resveratrol/Curcumin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.